AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's flagship product Ampligen is a double-stranded ribonucleic acid (dsRNA) molecule being developed for globally important cancers, viral diseases and disorders of the immune system. The Alferon N Injection (Interferon alfa) is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older. It is also approved in Argentina for the treatment of refractory patients that failed or were intolerant to treatment with recombinant interferons. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS).
Back to dashboard
Company Information
About this company
Key people
William M. Mitchell
Independent Chairman of the Board
Thomas K. Equels
President, Chief Executive Officer, Executive Vice Chairman of the Board
Robert Dickey
Chief Financial Officer
Peter W. Rodino
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Nancy K. Bryan
Independent Director
David I. Chemerow
Independent Director
Ted D. Kellner
Independent Director
Click to see more
Key facts
- Shares in issue39.89m
- EPICAIM
- ISINUS00901B3033
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$6.71m
- Employees19
- ExchangeNyse American LLC
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.